CoChat

Nigrostriatal rAAV-mediated GDNF Overexpression Induces Robust Weight Loss in a Rat Model of Age-related Obesity

Open access
Manfredsson, Fredric P, Tumer, Nihal, Erdos, Benedek, Landa, Tessa, Broxson, Christopher S, Sullivan, Layla F, Rising, Aaron C, Foust, Kevin D, Zhang, Yi, Muzyczka, Nicholas, Gorbatyuk, Oleg S, Scarpace, Philip J, Mandel, Ronald J · 2009 · Molecular Therapy
Cited by 100

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Intraventricular administration of glial cell line-derived neurotrophic factor (GDNF) in primate and humans to study Parkinson's disease (PD) has revealed the potential for GDNF to induce weight loss. Our previous data indicate that bilateral continuous hypothalamic GDNF overexpression via recombinant adeno-associated virus (rAAV) results in significant failure to gain weight in young rats and weight loss in aged rats. Based on these previous results, we hypothesized that because the nigrostriatal tract passes through the lateral hypothalamus, motor hyperactivity mediated by nigrostriatal dopamine (DA) may have been responsible for the previously observed effect on body weight. In this study, we compared bilateral injections of rAAV2/5-GDNF in hypothalamus versus substantia nigra (SN) in aged Brown-Norway X Fisher 344 rats. Nigrostriatal GDNF overexpression resulted in significantly greater weight loss than rats treated in hypothalamus. The nigral or hypothalamic GDNF-induced weight loss was unrelated to motor activity levels of the rats, though some of the weight loss could be attributed to a transient reduction in food intake. Forebrain DA levels did not account for the observed effects on body weight, although GDNF-induced increases in nucleus accumbens DA may have partially contributed to this effect in the hypothalamic GDNF-treated group. However, only nigrostriatal GDNF overexpression induced activation of phosphorylated extracellular signal-regulated kinase (p-ERK) in a small population of corticotrophin-releasing factor [corticotrophin-releasing hormone (CRH)] neurons located specifically in the medial parvocellullar division (MPD) of the paraventricular nucleus of the hypothalamus. Activation of these hypothalamic CRH neurons likely accounted for the observed metabolic effects leading to weight loss in obese rats.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2009.45

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 42

  1. Lin, 1993, GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons, Science, 260, 1130, 10.1126/science.8493557 · DOI · Paper page
  2. Pascual, 2008, Absolute requirement of GDNF for adult catecholaminergic neuron survival, Nat Neurosci, 11, 755, 10.1038/nn.2136 · DOI · Paper page
  3. Bespalov, 2007, GDNF family receptor complexes are emerging drug targets, Trends Pharmacol Sci, 28, 68, 10.1016/j.tips.2006.12.005 · DOI · Paper page
  4. Jing, 1996, GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-α, a novel receptor for GDNF, Cell, 85, 1113, 10.1016/S0092-8674(00)81311-2 · DOI · Paper page
  5. Treanor, 1996, Characterization of a multicomponent receptor for GDNF, Nature, 382, 80, 10.1038/382080a0 · DOI · Paper page
  6. Trupp, 1999, Ret-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells, J Biol Chem, 274, 20885, 10.1074/jbc.274.30.20885 · DOI · Paper page
  7. Mograbi, 2001, Glial cell line-derived neurotrophic factor-stimulated phosphatidylinositol 3-kinase and Akt activities exert opposing effects on the ERK pathway: importance for the rescue of neuroectodermic cells, J Biol Chem, 276, 45307, 10.1074/jbc.M101220200 · DOI
  8. Zigmond, 2006, Triggering endogenous neuroprotective mechanisms in Parkinson's disease: studies with a cellular model, J Neural Transm Suppl, 439, 10.1007/978-3-211-45295-0_66 · DOI
  9. Golden, 1999, Expression of neurturin, GDNF, and GDNF family-receptor mRNA in the developing and mature mouse, Exp Neurol, 158, 504, 10.1006/exnr.1999.7127 · DOI · Paper page
  10. Zhang, 1997, Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys, J Pharmacol Exp Ther, 282, 1396, 10.1016/S0022-3565(24)36963-0 · DOI
  11. Kordower, 1999, Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease, Ann Neurol, 46, 419, 10.1002/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q · doi:10.1002/1531-8249(199909)46:3<419::aid-ana21>3.0.co;2-q
  12. Nutt, 2003, Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD, Neurology, 60, 69, 10.1212/WNL.60.1.69 · DOI · Paper page
  13. Patel, 2005, Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study, Ann Neurol, 57, 298, 10.1002/ana.20374 · DOI · Paper page
  14. Tumer, 2006, Hypothalamic rAAV-mediated GDNF gene delivery ameliorates age-related obesity, Neurobiol Aging, 27, 459, 10.1016/j.neurobiolaging.2005.03.018 · DOI
  15. Lindvall, 1978, Anatomy of the dopaminergic neuron systems in the rat brain, Adv Biochem Psychopharmacol, 19, 1
  16. Ungerstedt, 1971, Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system, Acta Physiol Scand Suppl, 367, 95, 10.1111/j.1365-201X.1971.tb11001.x · DOI · Paper page
  17. Sotak, 2005, Dysregulation of dopamine signaling in the dorsal striatum inhibits feeding, Brain Res, 1061, 88, 10.1016/j.brainres.2005.08.053 · DOI
  18. Kirik, 2000, Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system, J Neurosci, 20, 4686, 10.1523/JNEUROSCI.20-12-04686.2000 · DOI · Paper page
  19. Gorbatyuk, 2001, Localization of agmatine in vasopressin and oxytocin neurons of the rat hypothalamic paraventricular and supraoptic nuclei, Exp Neurol, 171, 235, 10.1006/exnr.2001.7746 · DOI
  20. Khan, 2007, Catecholaminergic control of mitogen-activated protein kinase signaling in paraventricular neuroendocrine neurons in vivo and in vitro: a proposed role during glycemic challenges, J Neurosci, 27, 7344, 10.1523/JNEUROSCI.0873-07.2007 · DOI · Paper page
  21. Georgievska, 2002, Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer, Exp Neurol, 177, 461, 10.1006/exnr.2002.8006 · DOI · Paper page
  22. Aoi, 2000, The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages, Neurosci Res, 36, 319, 10.1016/S0168-0102(00)00097-3 · DOI
  23. Hoane, 1999, Differential in vivo effects of neurturin and glial cell-line-derived neurotrophic factor, Exp Neurol, 160, 235, 10.1006/exnr.1999.7175 · DOI
  24. Lapchak, 1997, Glial cell line-derived neurotrophic factor: distribution and pharmacology in the rat following a bolus intraventricular injection, Brain Res, 747, 92, 10.1016/S0006-8993(96)01265-6 · DOI
  25. Gash, 1995, Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys, J Comp Neurol, 363, 345, 10.1002/cne.903630302 · DOI · Paper page
  26. Horger, 1998, Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons, J Neurosci, 18, 4929, 10.1523/JNEUROSCI.18-13-04929.1998 · DOI · Paper page
  27. Palmiter, 2007, Is dopamine a physiologically relevant mediator of feeding behavior?, Trends Neurosci, 30, 375, 10.1016/j.tins.2007.06.004 · DOI · Paper page
  28. Li, 1997, Leptin gene expression increases with age independent of increasing adiposity in rats, Diabetes, 46, 2035, 10.2337/diab.46.12.2035 · DOI · Paper page
  29. Bassareo, 1999, Differential responsiveness of dopamine transmission to food-stimuli in nucleus accumbens shell/core compartments, Neuroscience, 89, 637, 10.1016/S0306-4522(98)00583-1 · DOI · Paper page
  30. Martel, 1996, Mesolimbic dopaminergic system activity as a function of food reward: a microdialysis study, Pharmacol Biochem Behav, 53, 221, 10.1016/0091-3057(95)00187-5 · DOI · Paper page
  31. Rosenblad, 2003, Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system, Eur J Neurosci, 17, 260, 10.1046/j.1460-9568.2003.02456.x · DOI · Paper page
  32. Liu, 1999, Is green fluorescent protein toxic to the living cells?, Biochem Biophys Res Commun, 260, 712, 10.1006/bbrc.1999.0954 · DOI · Paper page
  33. Detrait, 2002, Reporter gene transfer induces apoptosis in primary cortical neurons, Mol Ther, 5, 723, 10.1006/mthe.2002.0609 · DOI · Paper page
  34. Kirik, 2002, Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system, J Neurosci, 22, 2780, 10.1523/JNEUROSCI.22-07-02780.2002 · DOI · Paper page
  35. Klein, 2006, Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins, Mol Ther, 13, 517, 10.1016/j.ymthe.2005.10.008 · DOI · Paper page
  36. Isacson, 2008, Future of cell and gene therapies for Parkinson's disease, Ann Neurol, 64, S122, 10.1002/ana.21473 · DOI
  37. Kordower, 2000, Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease, Science, 290, 767, 10.1126/science.290.5492.767 · DOI · Paper page
  38. Eslamboli, 2005, Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease, J Neurosci, 25, 769, 10.1523/JNEUROSCI.4421-04.2005 · DOI · Paper page
  39. Zolotukhin, 2002, Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors, Methods, 28, 158, 10.1016/S1046-2023(02)00220-7 · DOI · Paper page
  40. Ben-Barak, 1984, Phylogenetic cross-reactivities of monoclonal antibodies produced against rat neurophysin, Cell Mol Neurobiol, 4, 339, 10.1007/BF00733596 · DOI
  41. Erdem, 2002, Effect of exercise on mRNA expression of select adrenal medullary catecholamine biosynthetic enzymes, J Appl Physiol, 93, 463, 10.1152/japplphysiol.00627.2001 · DOI
  42. Manfredsson, 2007, rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease, Exp Neurol, 207, 289, 10.1016/j.expneurol.2007.06.019 · DOI

Cited by

See all 100

Metadata

Authors
Manfredsson, F. P., Tumer, N., Erdos, B., Landa, T., Broxson, C. S., Sullivan, L. F., Rising, A. C., Foust, K. D., Zhang, Y., Muzyczka, N., Gorbatyuk, O. S., Scarpace, P. J., & Mandel, R. J.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2009-06
Volume
17
Issue
6
Pages
980-991
ISSN
1525-0016 (ISSN-L)
OpenAlex
W1998232945
Cited by
100
References
6
FWCI
4.22
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nigrostriatal rAAV-mediated GDNF Overexpression Induces Robust Weight Loss in a Rat Model of Age-related Obesity. https://app.cochat.ai/papers/10.1038/mt.2009.45
The paper
Manfredsson, F. P., Tumer, N., Erdos, B., Landa, T., Broxson, C. S., Sullivan, L. F., Rising, A. C., Foust, K. D., Zhang, Y., Muzyczka, N., Gorbatyuk, O. S., Scarpace, P. J., & Mandel, R. J. (2009). Nigrostriatal rAAV-mediated GDNF Overexpression Induces Robust Weight Loss in a Rat Model of Age-related Obesity. Molecular Therapy. https://doi.org/10.1038/mt.2009.45

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.